{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","name":"Bounded Semaglutide once signal: semaglutide (1.8%) versus placebo (2.2%)","doi":"10.17605/OSF.IO/F9UBP","doi_status":"minted","osf_url":"https://osf.io/f9ubp/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_ef38bd394801435c/chain","content_hash":"sha256:4ec7e520c621fabde58a8862734f7b29efe8f8fd8f455bc02feec1e3d84540bc","provenance_passport":{"publication_id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","submission_id":"c0988830-d72e-4e01-9492-82269d8fd762","artifact_type":"alpha_memo","decision":"accept","content_hash":"sha256:4ec7e520c621fabde58a8862734f7b29efe8f8fd8f455bc02feec1e3d84540bc","persistent_identifiers":{"doi":"10.17605/OSF.IO/F9UBP","osf_url":"https://osf.io/f9ubp/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_ef38bd394801435c","dw_chain_url":"https://provenance.researka.org/artifacts/claim_ef38bd394801435c/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","object_type":"publication","parent_object_id":"c0988830-d72e-4e01-9492-82269d8fd762","title":"Bounded Semaglutide once signal: semaglutide (1.8%) versus placebo (2.2%)","body_markdown":"**Selected angle:** `source`\n\n## One-sentence thesis\n\nThe cited direct receipts support a bounded working claim: semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001).\n\n**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.\n\n## Why this is surprising\n\nThe surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in patients with overweight/obesity and established cardiovascular disease, without diabetes; adults with preexisting cardiovascular disease, overweight or obesity, without diabetes; participants with overweight or obesity without type 2 diabetes. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.\n\n## Evidence Landscape\n\n_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._\n\n**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?\n\n## Evidence receipts\n\n- `fact_id=149514` (`A_core`) — semaglutide (1.8%) versus placebo (2.2%) doi=10.1038/s41591-024-03015-5\n- `fact_id=144494` (`A_core`) — At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001). doi=10.1038/s41591-024-02996-7\n- `fact_id=137772` (`A_core`) — 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo) doi=10.1111/dom.14863\n- `fact_id=75386` (`A_core`) — a greater proportion treated with semaglutide were normoglycemic (69.5% vs. 35.8%; P < 0.0001) doi=10.2337/dc24-0491\n- `fact_id=137455` (`A_core`) — 94.0% of the participants had a baseline body mass index ≥30 kg/m² doi=10.1016/j.amjcard.2024.04.041\n\n## Context receipts\n\n_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._\n\n- `fact_id=145389` (`A_core`) — More participants achieved weight loss ≥5% from baseline at week 104 with semaglutide (77.1%) versus placebo (34.4%; P<0.0001). doi=10.1038/s41591-022-02026-4\n\n## What this changes\n\n_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._\n\nTreat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.\n\n## Limitations\n\n- This is an alpha memo, not a settled review, guideline, or broad consensus claim.\n- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.\n- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.\n- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.\n- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## What would weaken this\n\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## Strongest counter-evidence\n\n- `fact_id=137771` (`A_core`) — semaglutide 2.4 mg was associated with mean weight losses of 14.9%-17.4% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68 Source: Semaglutide for the treatment of overweight and obesity: A review\n","metadata":{"abstract":"The cited direct receipts support a bounded working claim: semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001).","article_type":"alpha_memo","counts":{"retrieved_count":5,"selected_count":5,"review_like_count":2,"primary_like_count":3,"year_start":2022,"year_end":2024},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v4-alpha-memo","integrity":null,"doi":"10.17605/OSF.IO/F9UBP","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"f9ubp","osf_url":"https://osf.io/f9ubp/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"f9ubp","url":"https://osf.io/f9ubp/","doi":"10.17605/OSF.IO/F9UBP"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_ef38bd394801435c","dw_chain_url":"https://provenance.researka.org/artifacts/claim_ef38bd394801435c/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_ef38bd394801435c/chain","dw_source_artifact_id":"source_2d692921e52e4313","dw_input_artifact_ids":["source_db90b882083d4ba6","source_898ecac2cb164328","source_0552cd02b0c14fcb","source_a31fb6d38d6f4328","source_84dafe9842134b72","source_14b0537b0b41476b"],"dw_step_id":"step_80dc4555210a4fa1","dw_step_hash":"16e64c90e7add81a13652d7bf2eb900231d46da857cec2e2cd02f06dd10fba01","dw_status":"registered","content_hash":"sha256:4ec7e520c621fabde58a8862734f7b29efe8f8fd8f455bc02feec1e3d84540bc","sha256":"sha256:4ec7e520c621fabde58a8862734f7b29efe8f8fd8f455bc02feec1e3d84540bc"},"created_at":"2026-06-05T05:30:38.461935+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a bounded working claim: semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001).","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_3","claim":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_4","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_5","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_6","claim":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._","candidate_sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","url":null},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","url":null},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","content_hash":"sha256:4ec7e520c621fabde58a8862734f7b29efe8f8fd8f455bc02feec1e3d84540bc","nodes":[{"id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","type":"publication","title":"Bounded Semaglutide once signal: semaglutide (1.8%) versus placebo (2.2%)"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a bounded working claim: semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001)."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._"},{"id":"claim_4","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_5","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_6","type":"claim","text":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._"},{"id":"source_1","type":"source","study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","year":2024,"doi":"10.1038/s41591-024-03015-5","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","year":2024,"doi":"10.1038/s41591-024-02996-7","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Semaglutide for the treatment of overweight and obesity: A review","year":2022,"doi":"10.1111/dom.14863","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","year":2024,"doi":"10.2337/dc24-0491","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"doi":"10.1016/j.amjcard.2024.04.041","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_1","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_2","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_3","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_4","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_5","type":"contains_claim"},{"from":"767dd1a7-1300-4f73-8821-ca5a468dbafd","to":"claim_6","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nLong-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLong-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSemaglutide for the treatment of overweight and obesity: A review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nEffect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLong-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"767dd1a7-1300-4f73-8821-ca5a468dbafd","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide for the treatment of overweight and obesity: A review","doi":"10.1111/dom.14863","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial","doi":"10.2337/dc24-0491","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}}]}